EcoDrugPlus

Neurotrophic Tyrosine Kinase, Receptor, Type 2b

Ensembl ID : ENSACIG00000014847
Gene Symbol: NTRK2B
1 Cross references
210 Possible Orthologues:

Nfe2 Like Bzip Transcription Factor 2a

Ensembl ID : ENSACIG00000020313
Gene Symbol: NFE2L2A
1 Cross references
205 Possible Orthologues:

Nicastrin

Ensembl ID : ENSACIG00000013106
Gene Symbol: NCSTN
2 Cross references
204 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSACIG00000016597
Gene Symbol: NAMPT
1 Cross references
219 Possible Orthologues:

Notch Receptor 1b

Ensembl ID : ENSACIG00000001768
Gene Symbol: NOTCH1B
1 Cross references
200 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSACIG00000023434
Gene Symbol: NFKB1
1 Cross references
202 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 2

Ensembl ID : ENSACIG00000020830
Gene Symbol: NR1H2
1 Cross references
304 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 4

Ensembl ID : ENSACIG00000000110
Gene Symbol: NR1H4
1 Cross references
388 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSACIG00000010799
Gene Symbol: NR3C1
2 Cross references
206 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 1 (Glucocorticoid Receptor)

Ensembl ID : ENSACIG00000006445
Gene Symbol: NR3C1
1 Cross references
207 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 2

Ensembl ID : ENSACIG00000016441
Gene Symbol: NR3C2
1 Cross references
209 Possible Orthologues:

Nucleotide-Binding Oligomerization Domain Containing 2

Ensembl ID : ENSACIG00000004283
Gene Symbol: NOD2
1 Cross references
167 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).